Stocks of Lupin, the pharma major and drug manufacturer were trading up at 4%, or 38.45 points on the BSE. On Wednesday the company shared news regarding a drug receiving USFDA approval. Lupin's Quetiapine Fumarate Extended-release tablets, recieved a USFDA approval.
The drug is used in the treatment of treatment of schizophrenia, acute manic or mixed episodes in bipolar I disorder alone.
The 6th largest pharmaceutical company by revenues, posted net profit at $381 million for its financial year ending 31 March 2017.
The stock at 2:15 PM was trading at 997 points.
